Metastatic malignant neoplasm in the brain Trials in Jacksonville, United States
Conditions / Metastatic malignant neoplasm in the brain / Jacksonville, United States
Metastatic malignant neoplasm in the brain has been the subject of sustained clinical investigation across multiple research sites.
13 total trials for this combination
Showing top 10 of 13 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05438212 | Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03994796 | Genetic Testing in Guiding Treatment for Patients With Brain Metastases | SUSPENDED | PHASE2 |
| NCT04114981 | Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease | ACTIVE_NOT_RECRUITING | — |
| NCT03418961 | S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | RECRUITING | PHASE3 |
| NCT04588246 | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery | TERMINATED | PHASE3 |
| NCT04511013 | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | RECRUITING | PHASE2 |
| NCT02595905 | Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases | COMPLETED | PHASE2 |
| NCT04647916 | Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT00096265 | Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer | TERMINATED | PHASE3 |
| NCT02589522 | Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors | ACTIVE_NOT_RECRUITING | — |